John Nuss - 03 Aug 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role: Chief Scientific Officer
Signature: /s/ Christopher Krueger, as Attorney-in-Fact
Issuer symbol: VTYX
Transactions as of: 03 Aug 2023
Net transactions value: -$353,986
Form type: 4
Filing time: 04 Aug 2023, 18:08:55 UTC
Previous filing: 05 Jul 2023
Next filing: 07 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VTYX	Common Stock	Options Exercise	$2,000	+10,000	+4.1%	$0.2000^*	254,815	03 Aug 2023	Direct
transaction	VTYX	Common Stock	Sale	$316,010	-8,887	-3.5%	$35.56	245,928	03 Aug 2023	Direct	F1, F2
transaction	VTYX	Common Stock	Sale	$39,976	-1,113	-0.45%	$35.92	244,815	03 Aug 2023	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VTYX	Stock Option (right to buy)	Options Exercise	$0	-10,000	-37%	$0.000000	16,778	03 Aug 2023	Common Stock	10,000	$0.2000	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2022.
F2	Represents the weighted average share price of an aggregate total of 8,887 shares sold in the price range of $34.78 to $35.775. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3	Represents the weighted average share price of an aggregate total of 1,113 shares sold in the price range of $35.78 to $36.52. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4	Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 1, 2020.